Src-Mediated Cross-Talk between Farnesoid X and Epidermal Growth Factor Receptors Inhibits Human Intestinal Cell Proliferation and Tumorigenesis

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Peng, Zhongsheng ^a   Raufman, Jean Pierre ^a   Xie, Guofeng ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; FARNESOID X RECEPTOR; GUGGULSTERONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN HT29; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; GROWTH REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR WEIGHT; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; EPITHELIAL CELLS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTESTINAL MUCOSA; ISOXAZOLES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PREGNENEDIONES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 84868305756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048461     Document Type: Article

References (42)

1. Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW, et al. (2010) Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta 1801: 683-692.
2. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y, (2006) FXR, a multipurpose nuclear receptor. Trends Biochem Sci 31: 572-580.
3. Wang YD, Chen WD, Moore DD, Huang W, (2008) FXR: a metabolic regulator and cell protector. Cell Res 18: 1087-1095.
4. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368.
5. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43: 2971-2974.
6. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, et al. (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296: 1703-1706.
7. Dussault I, Beard R, Lin M, Hollister K, Chen J, et al. (2003) Identification of gene-selective modulators of the bile acid receptor FXR. J Biol Chem 278: 7027-7033.
8. De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, et al. (2004) The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 49: 982-989.
9. Lax S, Schauer G, Prein K, Kapitan M, Silbert D, et al. (2011) Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer.
10. Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A, (2008) Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res 68: 9589-9594.
11. Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, et al. (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 328: 469-477.
12. Smith DL, Keshavan P, Avissar U, Ahmed K, Zucker SD, (2010) Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor. Carcinogenesis 31: 1100-1109.
13. Cheng K, Zimniak P, Raufman JP, (2003) Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells. Cancer Res 63: 6744-6750.
14. Cheng K, Xie G, Raufman JP, (2007) Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol 73: 1001-1012.
15. Cheng K, Raufman JP, (2005) Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Biochem Pharmacol 70: 1035-1047.
16. Xie G, Cheng K, Shant J, Raufman JP, (2009) Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol 296: G755-763.
17. Giordano C, Catalano S, Panza S, Vizza D, Barone I, et al. (2011) Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene 30: 4129-4140.
18. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, et al. (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6: 507-515.
19. Frucht H, Jensen RT, Dexter D, Yang WL, Xiao Y, (1999) Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clin Cancer Res 5: 2532-2539.
20. Yang WL, Frucht H, (2000) Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells. Carcinogenesis 21: 1789-1793.
21. Yarden Y, (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37Suppl 4: S3-8.
22. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, et al. (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274: 8335-8343.
23. Sato K, Sato A, Aoto M, Fukami Y, (1995) c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem Biophys Res Commun 215: 1078-1087.
24. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, et al. (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38: 2258-2264.
25. Wan CW, McKnight MK, Brattain DE, Brattain MG, Yeoman LC, (1988) Different epidermal growth factor growth responses and receptor levels in human colon carcinoma cell lines. Cancer Lett 43: 139-143.
26. Overman MJ, Hoff PM, (2007) EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum 50: 1259-1270.
27. Venook AP, (2005) Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 103: 2435-2446.
28. Bhola NE, Grandis JR, (2008) Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 13: 1857-1865.
29. Hu T, Li C, (2010) Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer 9: 236.
30. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, et al. (2009) Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 9: 748-760.
31. Belo A, Cheng K, Chahdi A, Shant J, Xie G, et al. (2011) Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. Am J Physiol Gastrointest Liver Physiol 300: G749-G760.
32. Raufman JP, Cheng K, Saxena N, Chahdi A, Belo A, et al. (2011) Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion of human colon cancer cells. Biochem Biophys Res Commun 415: 319-324.
33. Belo A, Cheng K, Chahdi A, Shant J, Xie G, et al. (2011) Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. Am J Physiol Gastrointest Liver Physiol 300: G749-760.
34. Raufman JP, Samimi R, Shah N, Khurana S, Shant J, et al. (2008) Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia. Cancer Res 68: 3573-3578.
35. Haarmann-Stemmann T, Bothe H, Abel J, (2009) Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem Pharmacol 77: 508-520.
36. Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, et al. (2008) Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 68: 4406-4415.
37. An MJ, Cheon JH, Kim SW, Kim ES, Kim TI, et al. (2009) Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett 279: 93-100.
38. Sarfaraz S, Siddiqui IA, Syed DN, Afaq F, Mukhtar H, (2008) Guggulsterone modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in SENCAR mice. Carcinogenesis 29: 2011-2018.
39. Shishodia S, Aggarwal BB, (2004) Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 279: 47148-47158.
40. Singh SV, Choi S, Zeng Y, Hahm ER, Xiao D, (2007) Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res 67: 7439-7449.
41. Kapoor S, (2008) Guggulsterone: a potent farnesoid X receptor antagonist and its rapidly evolving role as a systemic anticarcinogenic agent. Hepatology 48: 2090-2091.
42. Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, et al. (2006) The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 66: 10120-10126.